Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2011 - 2026)

Ani Pharmaceuticals has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $15.5 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 14.12% year-over-year to $15.5 million; the TTM figure through Jun 2026 stood at $15.5 million (down 14.12% YoY), while the FY2025 annual figure was $12.2 million, down 38.64% from the prior year.
• Other Non-Current Liabilities came in at $15.5 million for Q2 2026 at Ani Pharmaceuticals, down from $16.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $35.1 million in Q4 2022 to a low of $10.6 million in Q3 2023.
• Average Other Non-Current Liabilities over 5 years is $19.2 million, with a median of $16.9 million recorded in 2025.
• Year-over-year, Other Non-Current Liabilities surged 311.95% in 2022 and sank 68.42% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $35.1 million in 2022, then tumbled by 31.54% to $24.0 million in 2023, then retreated by 17.4% to $19.8 million in 2024, then tumbled by 38.64% to $12.2 million in 2025, then grew by 27.71% to $15.5 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $15.5 million in Q2 2026, $16.4 million in Q1 2026, and $12.2 million in Q4 2025.